During the 13th Five-Year Plan period, China's pharmaceutical industry has undergone significant changes, with a number of health care reform policies such as consistency evaluation of generic drugs, centralized procurement and national talks being implemented continuously, and the industry as a whole is moving from marketing-driven to R&D innovation. At present, China is moving from a "pharmaceutical power" to a "pharmaceutical power", and pharmaceutical companies will usher in an unprecedented strategic opportunity period in the competition and win-win situation. At the same time, CPhI & P-MEC China is also in line with the development of the industry, in-depth layout of the industry chain, up to now has included API, fine chemicals and intermediates, excipients and dosage forms, preparations, natural extracts, biopharmaceuticals, contract customization, animal health, epidemic prevention materials, pharmaceutical machinery, packaging materials, laboratory instruments, pharmaceutical environmental protection and clean, pharmaceutical logistics, pharmaceutical automation and information technology, a total of 15 sections, become the global pharmaceutical industry vertical industry chain of the leading professional trade exchange event.